<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356456</url>
  </required_header>
  <id_info>
    <org_study_id>LSDH02-001</org_study_id>
    <nct_id>NCT04356456</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lumenato and Its Impact on Skin Parameters in Healthy Female Subjects</brief_title>
  <official_title>Randomized and Double-blinded Study Designed to Evaluate and Compare the Efficacy of a Once a Day Dietary Supplement to Reduce the Appearance of Wrinkles and Uneven Skin Tone and to Diminish the Appearance of Fine Lines and Wrinkles, to Affect Skin Complexion and Texture and to Strengthen the Skin Barrier, Over the Course of a 12-week Use Period, and 2 Weeks Post Usage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LycoRed Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LycoRed Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate perceived changes in skin health and appearance&#xD;
      after taking the study product daily for 12 weeks. The study product is a soft gel supplement&#xD;
      containing tomato oil. cored Lumenato supplement on skin health and appearance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study, randomized and double-blinded designed to evaluate and compare the&#xD;
      efficacy of a once a day dietary supplement to reduce the appearance of wrinkles and uneven&#xD;
      skin tone and to diminish the appearance of fine lines and wrinkles, to affect skin&#xD;
      complexion and texture and to strengthen the skin barrier, over the course of a 12-week use&#xD;
      period, and 2 weeks post usage.&#xD;
&#xD;
      Randomization at 1:1 ratio and is done by the sponsor. The product will arrive blinded (with&#xD;
      the kit number stated on the label) neither subjects nor study staff will know the identity&#xD;
      of the test products. A sequential number of bottles will be assigned to every enrolled&#xD;
      subject.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Covid-19&#xD;
  </why_stopped>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Actual">August 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization at 1:1 ratio for active or placebo</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VISIA-CR® images of each subject's face</measure>
    <time_frame>12 weeks</time_frame>
    <description>VISIA-CR® takes a series of standardized, reproducible digital facial images, inside of a controlled lighting environment. Subjects' front, left, and right views will be captured with their eyes gently closed using the following lighting parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Skin Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective &quot;Baseline Skin Questionnaire&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Study Product Questionnaire&quot;</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant perception of the study product and study experience as assessed by the &quot;End of Study Product Questionnaire&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Update Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective &quot;Update Skin Questionnaire&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events (AEs) observed during the study, classified by the investigator as to severity, relationship to the study product/protocol, and seriousness</measure>
    <time_frame>14 weeks</time_frame>
    <description>classified by the investigator</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance to the daily use of the Lycored Lumenato supplement through monitoring within ClaimIt (Weekly e-Diary)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weekly e-Diary</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Skin</condition>
  <arm_group>
    <arm_group_label>Lumenato Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lumenato oleoresin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>paraffin oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lumenato</intervention_name>
    <description>tomato oleoresin obtained from yellow dry tomato pulp</description>
    <arm_group_label>Lumenato Supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Resides in the United States&#xD;
&#xD;
          -  Generally healthy women between the ages of 35-55&#xD;
&#xD;
          -  Fitzpatrick skin types 2 or 3&#xD;
&#xD;
          -  Identifies as one of the following: White, Hispanic/Latino, or both White and&#xD;
             Hispanic/Latino&#xD;
&#xD;
          -  Type 2 on the Glogau Skin Classification scale&#xD;
&#xD;
          -  Has expressed interest in improving skin health and appearance&#xD;
&#xD;
          -  Willing and able to follow the procedures of the study&#xD;
&#xD;
          -  Willing to refrain from changing their diet or lifestyle significantly for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Able to understand the study requirements and activities in English, and provide&#xD;
             informed consent&#xD;
&#xD;
          -  Access to reliable internet service and smartphone in order to utilize the ClaimIt&#xD;
             software/app needed to remotely participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with Fitzpatrick skin types of 1, 4, 5 or 6&#xD;
&#xD;
          -  Known allergies or sensitivity to tomato, latex and/or potato&#xD;
&#xD;
          -  Current use or use within 1 month of study enrollment of hormonal therapies (including&#xD;
             hormonal contraceptives)&#xD;
&#xD;
          -  Current, regular use or regular use within 1 month of study enrollment of oral&#xD;
             steroids; regular use defined as &gt;10 consecutive days&#xD;
&#xD;
          -  Chronic or relapsing inflammatory and/or allergic skin conditions such as atopic&#xD;
             dermatitis, rosacea, psoriasis and alike including telangiectasias (&quot;spider veins&quot;)&#xD;
&#xD;
          -  Pregnant, lactating or breastfeeding women (within the last 6 months) or those&#xD;
             planning to become pregnant during the study period&#xD;
&#xD;
          -  Less than 2 years since diagnosis or treatment of skin cancer including basal cell&#xD;
             carcinoma, squamous cell carcinoma, melanoma- excluding actinic keratosis&#xD;
&#xD;
          -  Currently active herpes infections or currently on treatment for herpes infections&#xD;
&#xD;
          -  History of facial keloids&#xD;
&#xD;
          -  Current diagnosis of adult acne or currently on treatment for adult acne&#xD;
&#xD;
          -  Recent (&lt;6 months at enrollment) cardiovascular conditions such as stroke, transient&#xD;
             ischemic attack (TIA), or myocardial ischemia/infarction, recently on treatment for&#xD;
             congestive heart failure, or currently having vasculitis or vascular conditions&#xD;
&#xD;
          -  On potent blood thinners such as low-molecular weight heparin (LMWH), rivaroxaban,&#xD;
             apixaban, or other prescription blood thinners - excludes aspirin&#xD;
&#xD;
          -  Holds a current diagnosis of diabetes mellitus type I or II&#xD;
&#xD;
          -  Participants who have received facial irradiation within last year or are planning on&#xD;
             undergoing facial irradiation during the study&#xD;
&#xD;
          -  Chronic liver disease- excluding early stage non-alcoholic fatty liver disease (NAFLD)&#xD;
&#xD;
          -  Chronic kidney disease or recent (&lt;6 months at enrollment) acute kidney disease&#xD;
&#xD;
          -  Participants who currently take supplements containing carotenoids, lutein, melatonin&#xD;
             or tryptophan&#xD;
&#xD;
          -  Participants with occupations or lifestyle that require significant daily exposure to&#xD;
             the sun (defined as at least 1 hour of continuous outdoor sun exposure)&#xD;
&#xD;
          -  Participants who have had a sunburn in the last 2 weeks&#xD;
&#xD;
          -  Participants who use tanning salons or tanning products in the last 3 months&#xD;
&#xD;
          -  Participants who plan to undergo invasive facial procedures (injections, chemical&#xD;
             peeling, etc.) during the study or have undergone these procedures within 2 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Change in oral supplements or medications targeting skin health within 2 months prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Participants who are HIV positive&#xD;
&#xD;
          -  Participants who are immunosuppressed&#xD;
&#xD;
          -  Participants with a recent (&lt;2 months prior to enrollment) diagnosis of a psychiatric&#xD;
             condition&#xD;
&#xD;
          -  Participants having chronic connective tissue disorder affecting the skin (e.g.&#xD;
             Ehlers- Danlos syndrome, Marfan's Syndrome, Osteogenesis Imperfecta)&#xD;
&#xD;
          -  Participants with auto-immune skin diseases (e.g. scleroderma, psoriasis, lupus,&#xD;
             epidermolysis bullosa, bullous pemphigoid, temporal arteritis)&#xD;
&#xD;
          -  Participants who have been prescribed retinoids treatment (&lt;2 months prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Participants who meet either/or both of the following criteria with regards to smoking&#xD;
             habits (smoking includes cigarettes, e-cigs, pipes, hookah, cigars):&#xD;
&#xD;
          -  Who are current smokers (smoked at least 100 cigarettes, or tobacco/nicotine&#xD;
             equivalent, in her lifetime) and who continue to use these products&#xD;
&#xD;
          -  Who were former smokers (smoked at least 100 cigarettes, or tobacco/nicotine&#xD;
             equivalent, in her lifetime, but who have quit smoking) who have smoked within the&#xD;
             last year and/or were former smokers for 10 years&#xD;
&#xD;
          -  Participants who drink more than 14 drinks per week (more than 2 drinks per night)&#xD;
&#xD;
          -  Participants who use illicit or illegal drugs&#xD;
&#xD;
          -  Participants who are regular users of cannabis substances or substances derived from&#xD;
             cannabis such as CBD, CBD oils or balms, cannabis-containing edibles; vaping; smoking;&#xD;
             hookahs.&#xD;
&#xD;
          -  NOTE: regular use is defined as long stretches of inhaling or consuming these products&#xD;
             over several months or longer. Occasional, but not weekly, use of products with small&#xD;
             amounts of CBD-related compounds (e.g. waters with CBD infusions) are not considered&#xD;
             regular use.)&#xD;
&#xD;
          -  Participants who are planning a trip to the mountains or to a higher UV index region&#xD;
             during the study period&#xD;
&#xD;
          -  Any other medication, condition or disease that in the PI's opinion that may adversely&#xD;
             affect the participant's ability to complete the study, substantially impact the&#xD;
             study's integrity or may pose a significant risk to the participant&#xD;
&#xD;
          -  Participants who are experiencing perimenopausal or menopausal symptoms&#xD;
&#xD;
          -  Participants who have had a hysterectomy and/or both of their ovaries removed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Caswell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consumer product testing (CPT)</name>
      <address>
        <city>Fairfield</city>
        <state>New Jersey</state>
        <zip>07004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996 Sep;15(3):134-8. Review.</citation>
    <PMID>8948530</PMID>
  </reference>
  <reference>
    <citation>Groten K, Marini A, Grether-Beck S, Jaenicke T, Ibbotson SH, Moseley H, Ferguson J, Krutmann J. Tomato Phytonutrients Balance UV Response: Results from a Double-Blind, Randomized, Placebo-Controlled Study. Skin Pharmacol Physiol. 2019;32(2):101-108. doi: 10.1159/000497104. Epub 2019 Mar 5.</citation>
    <PMID>30836363</PMID>
  </reference>
  <reference>
    <citation>Havas F, Krispin S, Meléndez-Martínez AJ, von Oppen-Bezalel L. Preliminary Data on the Safety of Phytoene- and Phytofluene-Rich Products for Human Use including Topical Application. J Toxicol. 2018 Apr 15;2018:5475784. doi: 10.1155/2018/5475784. eCollection 2018.</citation>
    <PMID>29849613</PMID>
  </reference>
  <results_reference>
    <citation>Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988 Jun;124(6):869-71.</citation>
    <PMID>3377516</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutritional Supplement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

